AVIR MEXC RealStocks
Own real AVIR shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 14:30:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Atea Pharmaceuticals, Inc. (AVIR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.21, with a market capitalization of $338.08M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.87 to $6.45. This page covers its latest market performance, valuation, price trends and company information.
$338.08M | |
$4.17 | |
$4.26 | |
$4.07 | |
$4.22 | |
208.65K | |
279.75K | |
-- | |
$6.45 | |
$2.87 | |
-- | |
-- |
Atea Pharmaceuticals, Inc. (AVIR) is currently trading at $4.21 as of 2026-11-12 23:59:00, down 0.24% ($0.01) from the previous close of $4.22
During today's regular trading session, AVIR has traded between $4.07 and $4.27, with a trading volume of 208.65K shares. The current price is near the upper end of today's range.
Over the past seven days, Atea Pharmaceuticals, Inc. (AVIR) moved from $4.46 to $4.21, representing a decline of 5.54% ($0.25).
The stock traded between $4.04 and $4.50 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 268.63 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 37.5%
AVIR is currently trading at $4.21, placing it 37.5% of the way from its 52-week low of $2.87 to its 52-week high of $6.45. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 55 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Atea Pharmaceuticals, Inc. (AVIR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to AVIR, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between AVIR shares and USD.
AVIR Shares to USD
1.00 AVIR shares = 4.213 USD
Calculations are estimates based on the latest available price and are for reference only.